Trutakna (atacicept-vymj)
Vera Therapeutics (VERA)
ApprovedJul 7, 2026
Marketer take
Joins a fast-moving IgA nephropathy market (Filspari, Vanrafia, Fabhalta, Tarpeyo) and faces Vertex's povetacicept decision on Nov 30, 2026, so nephrology teams need sharp differentiation.
- Sponsor company
- Vera Therapeutics (VERA)
- Indication
- To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
- Therapeutic area
- Nephrology
- Event
- FDA approval
- Date
- Jul 7, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?